Morning Star | Qiming Venture Partners and Investors Honored on Touzijia 2025 Annual Equity Investment List
Recognizing investment institutions and individuals who have demonstrated sustained commitment and achieved outstanding results in the equity investment industry over the past year.
Recently, the Touzijia 2025 Annual Equity Investment Rankings were officially announced. The list recognizes institutions and individuals that have made sustained contributions and achieved outstanding results in the equity investment industry over the past year, collectively witnessing a new era for China's equity investment sector.
Qiming Venture Partners was named to the Top 50 Best VC Firms, Top 30 Best AI Investors, Top 35 Best Healthcare Investors, and Top 30 Best New Consumer Investors. Duane Kuang, Founding Managing Partner of Qiming Venture Partners, was named to the Top 30 Best VC Investors and Investor of the Year. William Hu, Managing Partner of Qiming Venture Partners, was named to the Top 10 Best Healthcare Investors.
Qiming Venture Partners received
Top 50 Best VC Firm of the Year
Top 30 Best AI Investor
Top 35 Best Healthcare Investor
Top 30 Best New Consumer Investor
Duane Kuang, Founding Managing Partner of Qiming Venture Partners
received
Top 30 Best VC Investor of the Year
Investor of the Year
William Hu, Managing Partner of Qiming Venture Partners
received
Top 10 Best Healthcare Investor of the Year
Touzijia noted that in 2025, a cohort of "far-sighted" VC/PE firms welcomed a harvest season alongside the domestic IPO rebound. Since the start of 2025, IPOs by VC/PE-backed startups have risen 35% year-over-year, breaking the downward trend that began in 2022. It is the "far-sighted" investments by VC/PE firms that have accelerated entrepreneurs' pace of technological iteration, enabling the market to produce a wave of globally leading new technologies — technologies that feed back into the industry and validate the long-term conviction of these "visionaries."
Source | Touzijia
Past Coverage
7 AI IPOs in 7 Months, Qiming Venture Partners: Investing in AI Is the Greatest Certainty in Chinese Investing Over the Next Two Decades Qiming Honors | 5 Qiming Venture Partners Investors Named to ChinaVenture's 2025 Investor Rankings Qiming Honors | 5 Qiming Venture Partners Investors Named to Forbes China's 2025 Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), Arbutus Biopharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.
Qiming Honors | Qiming Venture Partners Ranks Third on Zero2IPO's 2025 China VC List Among 8 Awards